Bausch Health Companies Inc Quick Ratio (BHC) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Bausch Health Companies Inc   (NYSE: BHC)

Bausch Health Companies Inc 's Quick Ratio

BHC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Bausch Health Companies Inc 's Cash & cash equivalent grew by 36.16 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Bausch Health Companies Inc 's Quick Ratio to 0.51, Quick Ratio remained below Bausch Health Companies Inc average.

Within Major Pharmaceutical Preparations industry 393 other companies have achieved higher Quick Ratio than Bausch Health Companies Inc in third quarter 2026. While Quick Ratio total ranking has improved so far during the Q3 2026 to 2391, from total ranking in the second quarter 2026 at 2484.

Explain Quick Ratio?
How much Cash & cash equivalents BHC´s has?
What are BHC´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/BHC/financial-strength
https://api.csimarket.com/api/v1/companies/BHC/fundamentals
https://api.csimarket.com/api/v1/companies/BHC/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
BHC Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change 187.43 %
Y / Y Cash & cash equivalent Change 89.98 %
Quick Ratio MRQ 0.51
BHC's Total Ranking # 2391
Seq. Current Liabilities Change 4.44 %
Seq. Cash & cash equivalent Change 36.16 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 394
Healthcare Sector # 740
Overall Market # 2622


Quick Ratio Statistics
High Average Low
3.95 0.58 0.13
(Mar 31 2015)   (Dec 31 2016)




Financial Statements
Bausch Health Companies Inc 's Current Liabilities $ 4,895 Millions Visit BHC's Balance sheet
Bausch Health Companies Inc 's Cash & cash equivalent $ 2,485 Millions Visit BHC's Balance sheet
Source of BHC's Sales Visit BHC's Sales by Geography


Cumulative Bausch Health Companies Inc 's Quick Ratio

BHC's Quick Ratio for the trailling 12 Months

BHC Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 7.94 %
Y / Y Cash & cash equivalent TTM Growth 29.31 %
Quick Ratio TTM 0.54
Total Ranking TTM # 2466
Seq. Current Liabilities TTM Growth 33.21 %
Seq. Cash & cash equivalent TTM Growth 20.5 %


On the trailing twelve months basis Due to rise in Current Liabilities in the Q3 2026 to $4,895.00 millions, cumulative Quick Ratio decreased to 0.54 above the BHC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 440 other companies have achieved higher Quick Ratio than Bausch Health Companies Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending second quarter 2026 at 4074.

Explain Quick Ratio?
How much Cash & cash equivalents BHC´s has?
What are BHC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 441
Healthcare Sector # 905
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
1.21 0.31 0.12
(Mar 31 2015)   (Dec 31 2021)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Arbutus Biopharma Corp  1.39 $ 337.490  Millions$ 241.933  Millions
Compass Pathways Plc  1.36 $ 443.979  Millions$ 325.863  Millions
Sarepta Therapeutics Inc   1.34 $ 878.776  Millions$ 656.353  Millions
Zai Lab Limited  1.32 $ 559.658  Millions$ 424.249  Millions
Urogen Pharma Ltd   1.31 $ 96.901  Millions$ 74.031  Millions
Ani Pharmaceuticals Inc  1.28 $ 420.758  Millions$ 328.717  Millions
Vertex Pharmaceuticals Inc  1.26 $ 6,303.300  Millions$ 5,000.300  Millions
Nature s Sunshine Products inc   1.22 $ 89.377  Millions$ 73.488  Millions
Ovid Therapeutics Inc   1.16 $ 13.811  Millions$ 11.858  Millions
Filana Therapeutics Inc   1.12 $ 46.990  Millions$ 41.946  Millions
Phathom Pharmaceuticals Inc   1.06 $ 184.558  Millions$ 174.902  Millions
Eton Pharmaceuticals Inc   1.03 $ 55.628  Millions$ 54.095  Millions
Oragenics Inc   1.02 $ 2.227  Millions$ 2.189  Millions
Geovax Labs Inc   1.01 $ 2.151  Millions$ 2.135  Millions
Akebia Therapeutics Inc   0.98 $ 159.254  Millions$ 162.349  Millions
Acadia Pharmaceuticals Inc   0.97 $ 322.365  Millions$ 332.217  Millions
Alkermes Plc   0.97 $ 631.314  Millions$ 651.933  Millions
Imunon Inc   0.95 $ 4.039  Millions$ 4.239  Millions
Geron Corporation  0.94 $ 69.794  Millions$ 74.248  Millions
Mirum Pharmaceuticals Inc   0.86 $ 243.188  Millions$ 283.080  Millions
Amphastar Pharmaceuticals Inc   0.86 $ 262.786  Millions$ 306.303  Millions
Aclaris Therapeutics Inc   0.84 $ 20.394  Millions$ 24.222  Millions
Seres Therapeutics Inc   0.84 $ 17.528  Millions$ 20.893  Millions
Jazz Pharmaceuticals Plc  0.80 $ 2,036.400  Millions$ 2,540.300  Millions
Zomedica Corp   0.80 $ 7.281  Millions$ 9.096  Millions
Pfizer Inc  0.79 $ 25,140.000  Millions$ 31,726.000  Millions
Xencor Inc  0.78 $ 59.622  Millions$ 76.266  Millions
Janux Therapeutics Inc   0.77 $ 41.818  Millions$ 54.247  Millions
Arcus Biosciences Inc   0.76 $ 151.000  Millions$ 199.000  Millions
Ligand Pharmaceuticals Incorporated  0.75 $ 374.303  Millions$ 500.569  Millions

Date modified: 2026-10-30T16:59:22+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.